LENZ Therapeutics (LENZ) Equity Average (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Equity Average data on file, last reported at $265.4 million in Q1 2026.

• Equity Average for Q1 2026 came in at $265.4 million, up 34.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $265.4 million (up 34.02% YoY), and the FY2025 annual result was $244.2 million, up 338.55% from the prior year.
• Equity Average rose to $265.4 million in Q1 2026 per LENZ's latest filing, from $239.1 million in the prior quarter.
• Over five years, Equity Average peaked at $372.7 million in Q1 2022 and troughed at -$81.1 million in Q4 2023.
• A 5-year average of $161.4 million and a median of $199.2 million in 2025 frame the typical range for Equity Average.
• The sharpest annual moves came in 2022 and 2023: Equity Average soared 598.61% in 2022, then tumbled 155.52% in 2023.
• A 5-year view of Equity Average shows it stood at $146.1 million in 2022, then slumped by 155.52% to -$81.1 million in 2023, then jumped by 358.42% to $209.7 million in 2024, then advanced by 14.05% to $239.1 million in 2025, then grew by 10.99% to $265.4 million in 2026.
• Business Quant data shows LENZ's Equity Average at $265.4 million in Q1 2026, $239.1 million in Q4 2025, and $200.1 million in Q3 2025.